Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02912949 · ClinicalTrials.gov registry record · Phase 2
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)
A Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion, sponsored by Partner Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 20
- Study locations
NCT02912949 is a Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion that is active but no longer recruiting, run by Partner Therapeutics. The registered enrollment target is 250 participants. The trial reports 20 study locations across 14 states.
The verdict
NCT02912949, a Phase 2 study of Solid Tumours Harboring NRG1 Fusion and NSCLC Harboring NRG1 Fusion, is active but no longer recruiting, sponsored by Partner Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
Conditions Studied
Interventions
- DRUG zenocutuzumab (MCLA-128)
Study Locations (20)
California
- The Oncology Institute of Hope and Innovation - Cerritos
- University of California Irvine - Irvine
- Stanford University - Palo Alto
- Sharp Memorial Hospital - San Diego
Florida
- Memorial Cancer Institute - Hollywood
- Cancer Specialists of North Florida - Jacksonville
- Mayo Clinic - Jacksonville
Montana
- Billings Clinic Cancer Center - Billings
- St. James Healthcare - Butte
Arizona
- Mayo Clinic - Phoenix
District of Columbia
- Georgetown University - Washington D.C.
Georgia
- Emory Winship Cancer Institute - Atlanta
Illinois
- Northwest Oncology & Hematology - Rolling Meadows
Massachusetts
- Dana Farber Cancer Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2015-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02912949
The ClinicalTrials.gov registry entry for NCT02912949 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Partner Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Solid Tumours Harboring NRG1 Fusion appearing as the primary indexed condition, and to 1 intervention - of which zenocutuzumab (MCLA-128) is the first listed.
NCT02912949 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Montana.
Frequently Asked Questions
What is clinical trial NCT02912949 about?
NCT02912949 is a clinical study titled "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)". This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)
What is the current status of trial NCT02912949?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2015-01. Estimated completion is 2026-12-31.
What conditions does trial NCT02912949 study?
This clinical trial studies the following conditions: Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion.
What interventions are being tested in trial NCT02912949?
The interventions under investigation include: zenocutuzumab (MCLA-128) (DRUG).
Who is sponsoring clinical trial NCT02912949?
This trial is sponsored by Partner Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02912949 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Solid Tumours Harboring NRG1 Fusion
All registered trials for this condition
NSCLC Harboring NRG1 Fusion
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.